1. Introduction {#sec1}
===============

Etanercept, a dimerized protein of the extracellular portion of the human TNF-α receptor fused to the Fc portion of human IgG1, is considered to be less immunogenic than other TNF-α antagonists.[@bib1] Nevertheless, with increased use of this drug in recent years, several immune-mediated adverse effects have been described. However, the mechanisms of pulmonary complications are incompletely understood.

Bronchoalveolar lavage (BAL) is widely used in the evaluation of immunosuppressed patients with respiratory abnormalities, and allows for analysis of lung injury patterns in drug-induced lung disease.[@bib2] However, very few data exist about BAL cellular analysis in etanercept-induced lung injury (EILI). Knowledge of BAL patterns in EILI may allow for a better understanding of underlying pathogenic processes in this disease. We present two cases of EILI in which BAL cellular analysis with immunophenotyping 1) helped identify distinct pathogenic mechanisms and 2) provided guidance for treatment without a need for tissue biopsy.

2. Case reports {#sec2}
===============

2.1. Case 1 {#sec2.1}
-----------

A 59-year-old white male with psoriasis and psoriatic arthritis presented with a one-month history of progressive dyspnea, fatigue, subjective fever, and night sweats. He was a former smoker and denied sick contacts, occupational/recreational exposure, or travel outside the Midwest. He had no history of lung disease. Prior therapy with methotrexate and oral corticosteroids was stopped due to side effects. He was switched to weekly etanercept (50 mg subcutaneously) 1.5 years prior to presentation, with good control of his rash and arthritis. Physical examination revealed hypoxemia (88--89% on 3 L O~2~) and bilateral fine crackles. There were no clinical features consistent with an articular or skin flare. Chest CT showed diffuse nodular and reticular interstitial opacities, bibasilar tree-in-bud opacities, and mediastinal lymphadenopathy ([Fig. 1](#fig1){ref-type="fig"}). Serum, urine and BAL testing for bacterial, viral, fungal, and mycobacterial infections, and tuberculin skin testing were negative. Spirometry showed a mild obstructive ventilatory defect and moderately decreased diffusing capacity ([Table 1](#tbl1){ref-type="table"}). BAL cell analysis revealed a CD4^+^-predominant lymphocytic alveolitis ([Table 2](#tbl2){ref-type="table"}). A presumptive diagnosis of EILI was made. Etanercept was stopped. Short term prednisone (0.5 mg/kg/day) was started with prompt resolution of symptoms and improvement in spirometry.

2.2. Case 2 {#sec2.2}
-----------

A 56-year-old white male with rheumatoid arthritis (RA) and associated mild pulmonary fibrosis (minimal basilar involvement stable over several years) was referred for dyspnea, dry cough, decreased exercise tolerance, and hypoxemia. Due to progression of extra-pulmonary RA symptoms on prednisone (5 mg/day), hydroxychloroquine (200 mg twice/day), and sulfasalazine (1000 mg twice/day), the latter two were stopped, and etanercept 50 mg subcutaneously weekly was added to the steroids four months before presentation. Joint symptoms rapidly resolved and the RA was under control as determined by the rheumatologist. However, the patient then developed increasing dyspnea with exertion. Spirometry demonstrated worsening restrictive defect ([Table 1](#tbl1){ref-type="table"}) since a prior study 6 months ago. Chest CT ([Fig. 2](#fig2){ref-type="fig"}) revealed increasing ground glass opacities (GGOs) and worsening interstitial infiltrates. Bacterial, viral, fungal or mycobacterial infections were ruled out. BAL revealed a CD8^+-^predominant lymphocytic alveolitis ([Table 2](#tbl2){ref-type="table"}), thought to represent etanercept-induced hypersensitivity pneumonitis. Etanercept was discontinued and prednisone increased to 30 mg/day. The patient rapidly improved, with return to baseline lung function ([Table 1](#tbl1){ref-type="table"}) and chest CT findings within 8 weeks.

3. Discussion {#sec3}
=============

We report two cases of EILI presenting with different BAL immunologic and radiologic patterns. Patient 1 presented with a CD4^+^-positive lymphocytic alveolitis, interstitial opacities, and mediastinal lymphadenopathy. In the face of negative infectious work-up (BAL fluid cytological and microbiologic analysis, fungal serology, tuberculin skin test), exclusion of psoriasis flare up (no skin or musculoskeletal findings), and lack of exposure to other medications with potential pulmonary side effects (discontinuation of methotrexate \> 1.5 years), the clinical presentation was most suggestive of a sarcoid-like syndrome.

Patient 2 exhibited a CD8^+^-positive lymphocytic alveolitis with GGOs and reticulo-nodular infiltrates suggestive of a hypersensitivity pneumonits-like reaction. We reached this diagnosis by excluding possible bacterial or granulomatous infections (BAL fluid cytological and microbiologic analysis, fungal serology); exacerbation of the pre-existing pulmonary fibrosis (clinically controlled RA; stable CT and PFTs before introduction of etanercept; BAL fluid cellular analysis not suggestive of UIP/NSIP/COP, the common presentations of RA-related pulmonary fibrosis), and medication-induced lung disease (discontinuation of sulfasalazine and hydroxychloroquine \> 4 months).

While the radiographic features of our patients are in agreement with the published literature,[@bib3; @bib4; @bib5] BAL patterns in EILI are not well defined. In fact, only one case of CD8^+^ alveolitis associated with EILI is reported.[@bib3] Interestingly, we did find two reports of CD4^+^-positive lymphocytic alveolitis in EILI. However, both patients underwent further invasive diagnostic biopsies (transbronchial or VATS) before treatment with systemic steroids was started.[@bib6; @bib7]

Our report emphasizes that EILI can present with distinct BAL immunologic patterns. We speculate that a sarcoid-like reaction (patient 1) and a hypersensitivity pneumonitis-like reaction (patient 2) represent two different, but steroid-sensitive, manifestations of EILI. Interestingly, paradoxical granulomatous reactions have been described before in patients receiving etanercept. These reactions appear to be more common in patients with underlying RA or psoriasis (as seen in our patients). A potential explanation is less robust TNF binding and quicker TNF release[@bib8] by etanercept than with other anti-TNF-α monoclonal antibodies. Subsequently the residual TNF-α activity induces CD4+ Th1-cells activation and increases production of IFN-α. The elevated IFN-α unopposed by an optimal TNF-α activity enhances the survival and proliferation of CD8^+^ blasts[@bib9] and IFN-γ secretion from NK cells.[@bib10] In the presence of Th1 environment IFN-γ is a key event in granuloma formation.[@bib11] An excess of various interferon (α and γ) activity, a TNF-α-induced Th1 environment combined with increased susceptibility to airborne antigens may explain paradoxical pulmonary CD4+ or CD8+ granulomatous reaction seen in EILI.[@bib12]

In previously reported EILI cases, the diagnosis was established via open lung or transbronchial biopsies; BAL fluid analysis was used only to exclude infectious causes. Our report suggests that analysis of BAL cell differential and lymphocyte subtyping may obviate the need for tissue biopsy in EILI, and thereby, allows for targeted therapy while avoiding the potential complications of a more invasive procedure.

In conclusion, EILI can present with CD4^+^- or CD8^+^-positive lymphocytic alveolitis and distinct radiographic patterns, possibly representing a sarcoid or a hypersensitivity reaction phenotype. In either case, BAL cellular analysis may allow for correct diagnosis and initiation of steroid therapy without a need for tissue biopsy.
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![Radiographs of patient 1. (A) Chest X-ray (CXR) at presentation shows diffuse bilateral micronodular disease. (B, C) Chest CT at presentation shows bilateral nodular and reticular interstitial opacities, tree-in-bud opacities, mediastinal lymphadenopaty. In conjunction with the findings of a CD4^+^-predominant lymphocytic alveolitis, a diagnosis of etanercept-induced sarcoid-like reaction was made, and treatment with corticosteroids was initiated. (D) CXR at follow-up (6 weeks) shows resolution of diffuse micronodular opacities.](gr1){#fig1}

![Radiographs of patient 2. (A) Chest CT at baseline shows bibasilar micronodular disease with patchy GGO. (B) Chest CT at presentation shows worsening bilateral GGO and reticulo-nodular opacities. In conjunction with the findings of a CD8^+^-predominant lymphocytic alveolitis, a diagnosis of etanercept-induced hypersensitivity pneumonitis was made, and corticosteroid dose was increased. (C) Chest CT at follow-up (8 weeks) revealed resolution of ground glass opacities, persistent subpleural micronodular opacities.](gr2){#fig2}

###### 

Pulmonary function tests.

                            Patient 1    Patient 2                   
  ------------------------- ------------ ------------ -------------- ------------------------------
  FEV~1~ L, (% predicted)   2.56 (85)    2.74 (91)    2.12(62) (L)   **2.40** (**73)** (baseline)
  FVC L, (% predicted)      4.31 (108)   4.42 (111)   2.75(61) (L)   **3.11** (**77)** (baseline)
  DLCO (% predicted)        54 (L)       **86** (N)   n/a            n/a

###### 

Bronchoalveolar lavage cell analysis.

  BAL fluid analysis   Normal values    Patient 1      Patient 2
  -------------------- ---------------- -------------- --------------
  Total cells          13 ± 2 × 10^4^   345 × 10^4^    960 × 10^4^
  \% Macrophages       85 ± 1.6         64             59
  \% Neutrophils       1.6 ± 0.7        1              2
  \% Eosinophils       0.19 ± 0.06      0              3
  \% Lymphocytes       1.5 ± 2.5        35             36
  \% CD4:CD8           2.2 ± 0.3        **2.56** (H)   **0.15** (L)
